Afatinib
- PDF / 169,356 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 9 Downloads / 177 Views
1 S
Diarrhoea, rash and paronychia: case report A man in his 50’s developed rash, diarrhoea and paronychia during treatment with afatinib for squamous cell carcinoma of the lungs. The man was diagnosed with squamous cell carcinoma of the lungs in 2012, at the age of 53 years. He was initially treated with carboplatin and paclitaxel that showed a good response. But in April 2013, disease progression was noted with a malignant lesion in his right lumbar lymph node. Thus, he was enrolled in a LUX-LUNG-8 study, where he started receiving treatment with afatinib 40 mg/day from 25 April 2013. Subsequently, he developed grade 2 diarrhoea. The man’s diarrhoea was managed with loperamide. He also developed grade 3 rash and paronychia grade 2 [duration of treatment to reaction onset not stated]. Following development of rash, his afatinib dose was reduced to 30 mg/day and then it was further reduced to 20 mg/day. He received afatinib for 504 days in total (16.6 months)[not all outcomes stated]. Jian H, et al. Long-term efficacy of afatinib in a patient with squamous cell carcinoma of the lung and multiple ERBB family aberrations: afatinib in ERBB+ lung squamous 803515070 cell carcinoma. Anti-Cancer Drugs 30: 873-878, No. 8, Sep 2019. Available from: URL: http://doi.org/10.1097/CAD.0000000000000813
0114-9954/20/1830-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 14 Nov 2020 No. 1830
Data Loading...
